Strides Pharma witnessed a significant surge in its stock price, reaching an all-time high of ₹1,395 per share on Friday. The 3.8% intraday gain was triggered by the announcement that its wholly-owned subsidiary, Strides Pharma Global Pte. Limited, received approval from the U.S. Food & Drug Administration (USFDA) for a generic version of Theophylline extended-release tablets. This development strengthens Strides Pharma’s position in the U.S. market and adds to its robust product pipeline. The company, headquartered in Bengaluru, India, stands as a major player in the global pharmaceutical sector with a broad portfolio of branded and generic medications.

USFDA Approval Boosts Strides Pharma Shares

Stock Price Surge: Strides Pharma shares hit an all-time high of ₹1,395, registering a 3.8% increase in intraday trading on the Bombay Stock Exchange (BSE) on Friday.

FDA Approval for Generic Drug: The price jump followed the announcement that Strides Pharma Global Pte. Limited, a Singapore-based subsidiary, received approval for the generic version of Theophylline extended-release tablets (300 mg and 450 mg) from the USFDA.

Theophylline: A Key Drug for Chronic Lung Conditions

Therapeutic Use: Theophylline extended-release tablets are indicated for managing reversible airflow obstruction and symptoms associated with chronic asthma, emphysema, and bronchitis.

Market Value: The combined market size of the approved doses (300 mg and 450 mg) is approximately $11.5 million, with the 300 mg dosage alone contributing $10.8 million.

Manufacturing and Market Strategy

Production Facility: Strides Pharma confirmed that the Theophylline tablets will be manufactured at their flagship plant in KRS Gardens, Bangalore. This highlights the company's integrated manufacturing capabilities and strategic role in global pharmaceutical supply chains.

Consistent Relief for Patients: The extended-release formulation of Theophylline ensures prolonged drug release, reducing the frequency of dosing while providing consistent symptom relief, making it an effective treatment for chronic respiratory diseases.

Strides Pharma: A Leader in Global Pharmaceuticals

Company Overview: Headquartered in Bengaluru, Strides Pharma is a well-integrated pharmaceutical manufacturer, specializing in both branded and generic markets. The company also produces OTC products and nutraceuticals, catering to global demand.

Market Capitalization and Valuation: Strides Pharma boasts a market capitalization of ₹12,500 crore. Its shares are currently trading at a price-to-earnings ratio of 201 times, with an earnings per share (EPS) of ₹6.68.